Articles

Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business. Read More ›

The Oncology Nursing Society (ONS) 39th Annual Congress attracted almost 3000 attendees from the United States and other parts of the world. Interviews with a random sample of attendees revealed that a common theme about what drew them to the meeting was the desire to expand their horizons—to gain new knowledge, meet new people, or to breathe new life into their careers. Read More ›

The American Cancer Society estimates that 24,050 new cases of multiple myeloma (MM) will be diagnosed in the United States in 2014 and that MM will cause approximately 11,090 deaths. The 5-year survival rate, by year of diagnosis, for people with MM has improved in recent decades in the United States (1985-1989, 27.4%; 1995, 33.4%; 2005, 44.9%2), and several treatment options are currently available. Read More ›

Angela Long is the founder and creator of Breast Investigators. Breast Investigators serves as a comprehensive resource guide to help those affected by breast cancer readily gain access to quality information, care, assistance, and support. Read More ›

Conferences: What can be said about them? They are absolutely necessary for challenges, progress, and outcomes that will contribute to better evidence-based treatment for patients. Read More ›

Several new drugs for the treatment of chronic lymphocytic leukemia (CLL) are considered major advances: 2 have been approved and 2 are under review by the US Food and Drug Administration (FDA). Read More ›

Deforia Lane, PhD, MT-BC, delivered the final address of the Fourth Annual Conference of the Academy of Oncology Nurse & Patient Navigators. Lane is the Associate Director of the Seidman Cancer Center, and Director of Music Therapy at University Hospitals of Cleveland, Seidman Cancer Center, and Rainbow Babies & Children’s Hospital. Read More ›

Many molecularly targeted agents that inhibit different pathways of hepatocarcinogenesis are under clinical development, and novel targets are being assessed in hepatocellular carcinoma (HCC). Read More ›

Patients with terminal hepatocellular carcinoma (HCC) may be a poorly understood group, according to the findings of quality-of-life research conducted by Lissi Hansen, PhD, RN, of Oregon Health and Science University in Portland, whose special interests are end-of-life issues and ethics. Read More ›

Subsets of patients with colon cancer may benefit from increased surveillance for toxicities associated with adjuvant FOLFOX (leucovorin, fluorouracil, oxaliplatin) treatment, Canadian researchers suggest, based on their detailed analysis of the toxicity profile of this common regimen and their identification of factors that predict toxicity. They presented their findings at the 2014 Gastrointestinal Cancers Symposium, held January 16-18, in San Francisco, California. Read More ›